Noradrenalin Hameln (Noradrenaline Tartrate)

Noradrenaline tartrate stimulates alpha‑1 adrenergic receptors, causing peripheral vasoconstriction, and activates beta‑1 receptors to a lesser degree, which modestly increases heart contractility and rate, together improving systemic blood pressure and perfusion.

The dose of Noradrenalin Hameln is determined by the prescribing clinician based on the patient’s condition, response, and monitoring parameters. No fixed regimen is provided here.

Safety data for noradrenaline in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Noradrenalin Hameln is a first‑line sympathomimetic vasopressor, offering potent alpha‑1 mediated vasoconstriction with modest beta‑1 activity. Compared with agents such as dopamine or phenylephrine, it provides more predictable blood‑pressure control and fewer tachyarrhythmic effects, making it a preferred choice in many critical‑care protocols.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

Noradrenalin Hameln is administered intravenously, typically as a continuous infusion. The infusion rate is titrated by the clinician to achieve target hemodynamic goals while monitoring blood pressure and cardiac rhythm.

Serious risks include severe hypertension, myocardial ischemia or infarction, arrhythmias, tissue necrosis at the infusion site, and pulmonary edema. Prompt recognition and adjustment of therapy are essential to mitigate these complications.

Patients with known hypersensitivity to noradrenaline or any component of the formulation should not receive the drug. Caution is also advised in individuals with uncontrolled cardiac arrhythmias, severe coronary artery disease, or peripheral vascular disorders.